A precision therapy against cancers driven by KIT/PDGFRA mutations

Erica K. Evans, Alexandra K. Gardino, Joseph L. Kim, Brian L. Hodous, Adam Shutes, Alison Davis, Xing Julia Zhu, Oleg Schmidt-Kittler, Doug Wilson, Kevin Wilson, Lucian DiPietro, Yulian Zhang, Natasja Brooijmans, Timothy P. LaBranche, Agnieszka Wozniak, Yemarshet K. Gebreyohannes, Patrick Schöffski, Michael Heinrich, Daniel J. DeAngelo, Stephen Miller & 6 others Beni Wolf, Nancy Kohl, Timothy Guzi, Nicholas Lydon, Andy Boral, Christoph Lengauer

    Research output: Contribution to journalArticle

    32 Citations (Scopus)

    Abstract

    Targeting oncogenic kinase drivers with small-molecule inhibitors can have marked therapeutic benefit, especially when administered to an appropriate genomically defined patient population. Cancer genomics and mechanistic studies have revealed that heterogeneous mutations within a single kinase can result in various mechanisms of kinase activation. Therapeutic benefit to patients can best be optimized through an in-depth understanding of the disease-driving mutations combined with the ability to match these insights to tailored highly selective drugs. This rationale is presented for BLU-285, a clinical stage inhibitor of oncogenic KIT and PDGFRA alterations, including activation loop mutants that are ineffectively treated by current therapies. BLU-285, designed to preferentially interact with the active conformation of KIT and PDGFRA, potently inhibits activation loop mutants KIT D816V and PDGFRA D842V with subnanomolar potency and also inhibits other well-characterized disease-driving KIT mutants both in vitro and in vivo in preclinical models. Early clinical evaluation of BLU-285 in a phase 1 study has demonstrated marked activity in patients with diseases associated with KIT (aggressive systemic mastocytosis and gastrointestinal stromal tumor) and PDGFRA (gastrointestinal stromal tumor) activation loop mutations.

    Original languageEnglish (US)
    Article numbereaao1690
    JournalScience Translational Medicine
    Volume9
    Issue number414
    DOIs
    StatePublished - Nov 1 2017

    Fingerprint

    Gastrointestinal Stromal Tumors
    Phosphotransferases
    Mutation
    Systemic Mastocytosis
    Neoplasms
    Genomics
    Therapeutics
    Pharmaceutical Preparations
    Population
    In Vitro Techniques

    ASJC Scopus subject areas

    • Medicine(all)

    Cite this

    Evans, E. K., Gardino, A. K., Kim, J. L., Hodous, B. L., Shutes, A., Davis, A., ... Lengauer, C. (2017). A precision therapy against cancers driven by KIT/PDGFRA mutations. Science Translational Medicine, 9(414), [eaao1690]. https://doi.org/10.1126/scitranslmed.aao1690

    A precision therapy against cancers driven by KIT/PDGFRA mutations. / Evans, Erica K.; Gardino, Alexandra K.; Kim, Joseph L.; Hodous, Brian L.; Shutes, Adam; Davis, Alison; Zhu, Xing Julia; Schmidt-Kittler, Oleg; Wilson, Doug; Wilson, Kevin; DiPietro, Lucian; Zhang, Yulian; Brooijmans, Natasja; LaBranche, Timothy P.; Wozniak, Agnieszka; Gebreyohannes, Yemarshet K.; Schöffski, Patrick; Heinrich, Michael; DeAngelo, Daniel J.; Miller, Stephen; Wolf, Beni; Kohl, Nancy; Guzi, Timothy; Lydon, Nicholas; Boral, Andy; Lengauer, Christoph.

    In: Science Translational Medicine, Vol. 9, No. 414, eaao1690, 01.11.2017.

    Research output: Contribution to journalArticle

    Evans, EK, Gardino, AK, Kim, JL, Hodous, BL, Shutes, A, Davis, A, Zhu, XJ, Schmidt-Kittler, O, Wilson, D, Wilson, K, DiPietro, L, Zhang, Y, Brooijmans, N, LaBranche, TP, Wozniak, A, Gebreyohannes, YK, Schöffski, P, Heinrich, M, DeAngelo, DJ, Miller, S, Wolf, B, Kohl, N, Guzi, T, Lydon, N, Boral, A & Lengauer, C 2017, 'A precision therapy against cancers driven by KIT/PDGFRA mutations', Science Translational Medicine, vol. 9, no. 414, eaao1690. https://doi.org/10.1126/scitranslmed.aao1690
    Evans EK, Gardino AK, Kim JL, Hodous BL, Shutes A, Davis A et al. A precision therapy against cancers driven by KIT/PDGFRA mutations. Science Translational Medicine. 2017 Nov 1;9(414). eaao1690. https://doi.org/10.1126/scitranslmed.aao1690
    Evans, Erica K. ; Gardino, Alexandra K. ; Kim, Joseph L. ; Hodous, Brian L. ; Shutes, Adam ; Davis, Alison ; Zhu, Xing Julia ; Schmidt-Kittler, Oleg ; Wilson, Doug ; Wilson, Kevin ; DiPietro, Lucian ; Zhang, Yulian ; Brooijmans, Natasja ; LaBranche, Timothy P. ; Wozniak, Agnieszka ; Gebreyohannes, Yemarshet K. ; Schöffski, Patrick ; Heinrich, Michael ; DeAngelo, Daniel J. ; Miller, Stephen ; Wolf, Beni ; Kohl, Nancy ; Guzi, Timothy ; Lydon, Nicholas ; Boral, Andy ; Lengauer, Christoph. / A precision therapy against cancers driven by KIT/PDGFRA mutations. In: Science Translational Medicine. 2017 ; Vol. 9, No. 414.
    @article{ffddcd1fec7743a0b0441fba70463ed8,
    title = "A precision therapy against cancers driven by KIT/PDGFRA mutations",
    abstract = "Targeting oncogenic kinase drivers with small-molecule inhibitors can have marked therapeutic benefit, especially when administered to an appropriate genomically defined patient population. Cancer genomics and mechanistic studies have revealed that heterogeneous mutations within a single kinase can result in various mechanisms of kinase activation. Therapeutic benefit to patients can best be optimized through an in-depth understanding of the disease-driving mutations combined with the ability to match these insights to tailored highly selective drugs. This rationale is presented for BLU-285, a clinical stage inhibitor of oncogenic KIT and PDGFRA alterations, including activation loop mutants that are ineffectively treated by current therapies. BLU-285, designed to preferentially interact with the active conformation of KIT and PDGFRA, potently inhibits activation loop mutants KIT D816V and PDGFRA D842V with subnanomolar potency and also inhibits other well-characterized disease-driving KIT mutants both in vitro and in vivo in preclinical models. Early clinical evaluation of BLU-285 in a phase 1 study has demonstrated marked activity in patients with diseases associated with KIT (aggressive systemic mastocytosis and gastrointestinal stromal tumor) and PDGFRA (gastrointestinal stromal tumor) activation loop mutations.",
    author = "Evans, {Erica K.} and Gardino, {Alexandra K.} and Kim, {Joseph L.} and Hodous, {Brian L.} and Adam Shutes and Alison Davis and Zhu, {Xing Julia} and Oleg Schmidt-Kittler and Doug Wilson and Kevin Wilson and Lucian DiPietro and Yulian Zhang and Natasja Brooijmans and LaBranche, {Timothy P.} and Agnieszka Wozniak and Gebreyohannes, {Yemarshet K.} and Patrick Sch{\"o}ffski and Michael Heinrich and DeAngelo, {Daniel J.} and Stephen Miller and Beni Wolf and Nancy Kohl and Timothy Guzi and Nicholas Lydon and Andy Boral and Christoph Lengauer",
    year = "2017",
    month = "11",
    day = "1",
    doi = "10.1126/scitranslmed.aao1690",
    language = "English (US)",
    volume = "9",
    journal = "Science Translational Medicine",
    issn = "1946-6234",
    publisher = "American Association for the Advancement of Science",
    number = "414",

    }

    TY - JOUR

    T1 - A precision therapy against cancers driven by KIT/PDGFRA mutations

    AU - Evans, Erica K.

    AU - Gardino, Alexandra K.

    AU - Kim, Joseph L.

    AU - Hodous, Brian L.

    AU - Shutes, Adam

    AU - Davis, Alison

    AU - Zhu, Xing Julia

    AU - Schmidt-Kittler, Oleg

    AU - Wilson, Doug

    AU - Wilson, Kevin

    AU - DiPietro, Lucian

    AU - Zhang, Yulian

    AU - Brooijmans, Natasja

    AU - LaBranche, Timothy P.

    AU - Wozniak, Agnieszka

    AU - Gebreyohannes, Yemarshet K.

    AU - Schöffski, Patrick

    AU - Heinrich, Michael

    AU - DeAngelo, Daniel J.

    AU - Miller, Stephen

    AU - Wolf, Beni

    AU - Kohl, Nancy

    AU - Guzi, Timothy

    AU - Lydon, Nicholas

    AU - Boral, Andy

    AU - Lengauer, Christoph

    PY - 2017/11/1

    Y1 - 2017/11/1

    N2 - Targeting oncogenic kinase drivers with small-molecule inhibitors can have marked therapeutic benefit, especially when administered to an appropriate genomically defined patient population. Cancer genomics and mechanistic studies have revealed that heterogeneous mutations within a single kinase can result in various mechanisms of kinase activation. Therapeutic benefit to patients can best be optimized through an in-depth understanding of the disease-driving mutations combined with the ability to match these insights to tailored highly selective drugs. This rationale is presented for BLU-285, a clinical stage inhibitor of oncogenic KIT and PDGFRA alterations, including activation loop mutants that are ineffectively treated by current therapies. BLU-285, designed to preferentially interact with the active conformation of KIT and PDGFRA, potently inhibits activation loop mutants KIT D816V and PDGFRA D842V with subnanomolar potency and also inhibits other well-characterized disease-driving KIT mutants both in vitro and in vivo in preclinical models. Early clinical evaluation of BLU-285 in a phase 1 study has demonstrated marked activity in patients with diseases associated with KIT (aggressive systemic mastocytosis and gastrointestinal stromal tumor) and PDGFRA (gastrointestinal stromal tumor) activation loop mutations.

    AB - Targeting oncogenic kinase drivers with small-molecule inhibitors can have marked therapeutic benefit, especially when administered to an appropriate genomically defined patient population. Cancer genomics and mechanistic studies have revealed that heterogeneous mutations within a single kinase can result in various mechanisms of kinase activation. Therapeutic benefit to patients can best be optimized through an in-depth understanding of the disease-driving mutations combined with the ability to match these insights to tailored highly selective drugs. This rationale is presented for BLU-285, a clinical stage inhibitor of oncogenic KIT and PDGFRA alterations, including activation loop mutants that are ineffectively treated by current therapies. BLU-285, designed to preferentially interact with the active conformation of KIT and PDGFRA, potently inhibits activation loop mutants KIT D816V and PDGFRA D842V with subnanomolar potency and also inhibits other well-characterized disease-driving KIT mutants both in vitro and in vivo in preclinical models. Early clinical evaluation of BLU-285 in a phase 1 study has demonstrated marked activity in patients with diseases associated with KIT (aggressive systemic mastocytosis and gastrointestinal stromal tumor) and PDGFRA (gastrointestinal stromal tumor) activation loop mutations.

    UR - http://www.scopus.com/inward/record.url?scp=85032840410&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85032840410&partnerID=8YFLogxK

    U2 - 10.1126/scitranslmed.aao1690

    DO - 10.1126/scitranslmed.aao1690

    M3 - Article

    VL - 9

    JO - Science Translational Medicine

    JF - Science Translational Medicine

    SN - 1946-6234

    IS - 414

    M1 - eaao1690

    ER -